Volume 15, Issue 10, Pages (October 2007)

Slides:



Advertisements
Similar presentations
Molecular Therapy - Methods & Clinical Development
Advertisements

Volume 19, Issue 2, Pages (February 2011)
Volume 19, Issue 7, Pages (July 2011)
Volume 19, Issue 1, Pages (January 2011)
Volume 15, Issue 6, Pages (June 2007)
Volume 16, Issue 3, Pages (March 2008)
Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a γ-retroviral.
A Roadmap to Safe, Efficient, and Stable Lentivirus-Mediated Gene Therapy with Hematopoietic Cell Transplantation  Anton Neschadim, MSc, J. Andrea McCart,
Volume 25, Issue 9, Pages (September 2017)
Volume 17, Issue 11, Pages (November 2009)
Volume 25, Issue 3, Pages (March 2017)
Volume 20, Issue 7, Pages (July 2012)
Correction of a mouse model of sickle cell disease: lentiviral/antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cells.
Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer by Andrew Wilber,
Volume 25, Issue 3, Pages (March 2017)
Volume 17, Issue 9, Pages (September 2009)
Volume 17, Issue 8, Pages (August 2009)
Volume 15, Issue 1, Pages (January 2007)
Volume 12, Issue 6, Pages (December 2005)
Volume 14, Issue 4, Pages (October 2006)
Transient Gene Expression by Nonintegrating Lentiviral Vectors
Neeltje A Kootstra, Ryusuke Matsumura, Inder M Verma  Molecular Therapy 
Volume 20, Issue 5, Pages (May 2012)
Lentiviral-mediated RNAi inhibition of Sbds in murine hematopoietic progenitors impairs their hematopoietic potential by Amy S. Rawls, Alyssa D. Gregory,
Volume 20, Issue 5, Pages (May 2012)
Volume 23, Issue 5, Pages (May 2015)
Volume 10, Issue 1, Pages (July 2004)
Transduction of Human Embryonic Stem Cells by Foamy Virus Vectors
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 12, Issue 3, Pages (September 2005)
Volume 25, Issue 9, Pages (September 2017)
Volume 20, Issue 5, Pages (May 2012)
Expression of the MOZ-TIF2 oncoprotein in mice represses senescence
Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor  Alexander Falkenhagen, Jastaranpreet Singh, Sabah Asad, Danila Leontyev,
Volume 15, Issue 6, Pages (June 2007)
Volume 25, Issue 8, Pages (August 2017)
Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals  Clare Pridans,
Volume 19, Issue 1, Pages (January 2011)
Volume 20, Issue 10, Pages (October 2012)
Volume 19, Issue 3, Pages (March 2011)
Volume 18, Issue 4, Pages (April 2010)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Nucleic Acids
Volume 15, Issue 9, Pages (September 2007)
Volume 19, Issue 2, Pages (February 2011)
Volume 6, Issue 5, Pages (November 2002)
Volume 16, Issue 4, Pages (April 2008)
Volume 8, Issue 6, Pages (December 2003)
Volume 15, Issue 8, Pages (August 2007)
Volume 15, Issue 11, Pages (November 2007)
Volume 21, Issue 5, Pages (May 2013)
Volume 15, Issue 4, Pages (April 2007)
Volume 21, Issue 8, Pages (August 2013)
Morvarid Moayeri, Teresa S. Hawley, Robert G. Hawley  Molecular Therapy 
Volume 11, Issue 6, Pages (June 2005)
Molecular Therapy - Methods & Clinical Development
The Effect of Distance on Long-Range Chromatin Interactions
Volume 17, Issue 11, Pages (November 2009)
Volume 15, Issue 9, Pages (September 2007)
Volume 23, Issue 4, Pages (April 2015)
Volume 19, Issue 1, Pages (January 2011)
Volume 33, Issue 1, Pages (July 2010)
Volume 7, Issue 3, Pages (March 2003)
Volume 11, Issue 5, Pages (May 2005)
Volume 20, Issue 11, Pages (November 2012)
Engineering Globin Gene Expression
A Double-Switch Vector System Positively Regulates Transgene Expression by Endogenous microRNA Expression (miR-ON Vector)  Mario Amendola, Alice Giustacchini,
Volume 13, Issue 1, Pages (January 2006)
Volume 17, Issue 2, Pages (February 2009)
Presentation transcript:

Volume 15, Issue 10, Pages 1863-1871 (October 2007) Improved Human β-globin Expression from Self-inactivating Lentiviral Vectors Carrying the Chicken Hypersensitive Site-4 (cHS4) Insulator Element  Paritha I Arumugam, Jessica Scholes, Natalya Perelman, Ping Xia, Jiing-Kuan Yee, Punam Malik  Molecular Therapy  Volume 15, Issue 10, Pages 1863-1871 (October 2007) DOI: 10.1038/sj.mt.6300259 Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 1 Vector design. (a) The BG vector was constructed using a self-inactivating (SIN) lentiviral backbone containing the human β-globin (hβ-globin) gene and promoter and the locus control region (LCR) consisting of hypersensitive sites (HSs) 2, 3, and 4 cloned in the reverse orientation to the viral transcriptional unit, downstream of the rev response element (RRE) and the central polypurine tract (cPPT). (b) The BG-I vector was designed with a 1.2-kb chicken HS4 (cHS4) insulator element inserted to replace the U3 promoter/enhancer deletion (U3Δ). Upon proviral integration into host genome, the U3 region containing the 1.2-kb cHS4 is copied over to the 5′ long terminal repeat. Two additional vectors, (c) BGM and (d) BGM-I, were constructed that carried the mutant P140K methyl guanine methyl transferase (MGMTP140K) complementary DNA in a direction opposite to the hβ-globin gene, under the control of human phosphoglycerate kinase promoter. Proviral forms of all vectors are shown. Molecular Therapy 2007 15, 1863-1871DOI: (10.1038/sj.mt.6300259) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 2 Human β-globin (hβ-globin) expression from BGM and BGM-I murine erythroleukemia (MEL) clones after β-chloro-nitrosourea compound selection. (a) Representative flow cytometry histograms of selected BGM and BGM-I clones, labeled with antibody to hβ-globin (filled histograms) overlaid with the fluorescence of similarly labeled un-transduced MEL clones (clear histograms). The percentage hβ-globin expression is indicated at the top right of the histogram overlays. (b) Cumulative data on the hβ-globin-expressing cells in BGM (open circles) and BGM-I clones (closed circles). (c) Coefficient of variation (CV) of hβ-globin expression of the BGM and BGM-I drug-selected MEL clones. The means are represented with a horizontal line and the mean ± SEM and P-values are denoted in the figure. Molecular Therapy 2007 15, 1863-1871DOI: (10.1038/sj.mt.6300259) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 3 Human β-globin (hβ-globin) expression from BGM and BGM-I murine erythroleukemia (MEL) clones without selection. (a) Proportion of hβ-globin-expressing cells/clone transduced with the BGM vector (open circles) and BGM-I (filled circles). Clones were screened for transduction by polymerase chain reaction. (b) Coefficient of variation and (c) mean fluorescence intensity (MFI) of hβ-globin expression/clone in unselected BGM and BGM-MEL clones. Molecular Therapy 2007 15, 1863-1871DOI: (10.1038/sj.mt.6300259) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 4 Human β-globin (hβ-globin) expression from vectors carrying no drug selection cassette, BG and BG-I. (a) Representative fluorescence-activated cell sorting histograms of BG and BG-I single-integrant clones (filled histograms), overlaid with the fluorescence of un-transduced murine erythroleukemia (MEL) clones (clear histograms). The proportion of hβ-globin-expressing cells is shown on the x-axis and values are indicated at the top right of the histogram overlays. (b) Proportion of hβ-globin expressing cells/clone. (c) The coefficient of variation (CV) of the hβ-globin expression in BG (empty squares) and BG-I (filled squares) transduced MEL clones. Clones were screened for vector integrants by polymerase chain reaction. Mean ± SEM and P-values are shown in the figure. Molecular Therapy 2007 15, 1863-1871DOI: (10.1038/sj.mt.6300259) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 5 Human β-globin (hβ-globin) messenger RNA (mRNA) expression from murine erythroleukemia (MEL) clones transduced with insulated and un-insulated vectors. (a) A representative ribonuclease protection assay showing hβ-globin mRNA expression in unselected BGM, BGM-I, and un-transduced MEL clones. Murine α-globin expression served as the internal loading control, against which hβ-globin expression was normalized. Quantification of hβ-globin mRNA (percentage hβ/total mα) by phosphorimaging in (b) unselected BGM (open bar) and BGM-I (hatched bar) transduced MEL clones, (c) selected BGM and BGM-I MEL clones, and (d) BG (open bar) and BG-I (checkered bar) MEL clones. Mean ± SEM and P-values are shown in the figure. Molecular Therapy 2007 15, 1863-1871DOI: (10.1038/sj.mt.6300259) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 6 Consistent and higher human β-globin (hβ-globin) expression in vivo from murine hematopoietic stem cells. (a) Representative fluorescence-activated cell sorting histograms of BGM and BGM-I group mice showing hβ-globin expression in peripheral blood red blood cells (RBCs) 5 months after bone marrow transplant. Insets show the same data as a dot-plot, demonstrating the distinct separation of hβ-globin-expressing cells even when present in a small proportion. (b) Cumulative data on the percentage of hβ-globin-expressing RBCs in BGM (open bar) and BGM-I (hatched bar) transplanted mice (n = 12). (c) The coefficient of variation (CV) of hβ-globin-expressing RBCs in vector transplanted mice. (d) Cellulose acetate electrophoresis of peripheral blood lysates at 4 months after transplantation showing mouse hemoglobin tetramers and a chimeric hemoglobin band composed of mα- and hβ-globin chains. (e) Quantification of the chimeric hemoglobin bands by densitometry in the BGM (open bar) and BGM-I (hatched bar) groups of mice. chim. Hb, chimeric hemoglobin. Molecular Therapy 2007 15, 1863-1871DOI: (10.1038/sj.mt.6300259) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions

Figure 7 Human β-globin (hβ-globin) expression in the clonal progeny of hematopoietic stem cells in secondary mice. (a) Representative dot-plot analysis of control, BGM, and BGM-I group mice showing hβ-globin expression in single-copy secondary spleen colony-forming units (CFU-Ss). Of note, even low proportions of hβ-globin-expressing cells were distinctly separate from non-expressing cells in each CFU-S. (b) Cumulative data on hβ-globin-expressing single-copy CFU-Ss of BGM (open circles) and BGM-I (closed circles). (c) The coefficient of variation (CV) of hβ-globin-expressing cells/CFU-S of BGM and BGM-I secondary mice. Molecular Therapy 2007 15, 1863-1871DOI: (10.1038/sj.mt.6300259) Copyright © 2007 The American Society of Gene Therapy Terms and Conditions